Verastem

Yahoo Finance • 12 days ago

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, April 02, 2026--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 141,000 restricted... Full story

Yahoo Finance • last month

Quant snapshot: Impala Platinum, Turkcell Iletisim lead strong buys as Evolus lag

Information Technology stocks lead the pack on quant strength in the latest screen, posting the highest average ratings among the sectors listed, while Health Care names rank at the bottom. The single highest-rated stock overall is Impala... Full story

Yahoo Finance • 5 months ago

Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment

Verastem, Inc. (NASDAQ:VSTM) is one of the top long-term biotechnology stocks to buy. On October 23, Verastem, Inc. (NASDAQ:VSTM) reported positive preliminary results from an ongoing phase 1/2a dose-escalation trial of vs-7375, an oral KR... Full story

Yahoo Finance • 8 months ago

Earnings call transcript: Verastem Q2 2025 sees revenue growth and FDA approval

Verastem Inc., a biopharmaceutical company, reported its financial results for the second quarter of 2025, highlighting a net product revenue of $2.1 million following the launch of its new cancer therapy. Despite a non-GAAP adjusted net l... Full story

Yahoo Finance • 9 months ago

Verastem stock rises after LGSOC treatment data published in medical journal

Investing.com -- Verastem Inc (NASDAQ:VSTM) stock gained 3.5% after the company announced that primary analysis data from its Phase 2 RAMP 201 clinical trial was published in the Journal of Clinical Oncology. The published data showed t... Full story

Yahoo Finance • 9 months ago

Verastem's cancer drug shows 31% response rate in ovarian cancer trial

BOSTON - Verastem Oncology (NASDAQ:VSTM), a clinical-stage biopharmaceutical company with a market capitalization of $259 million, reported that its combination therapy of avutometinib plus defactinib demonstrated a 31% overall response ra... Full story

Yahoo Finance • 9 months ago

Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies

PALM BEACH, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The global oncology market, including breakthrough treatments, is experiencing substantial growth, with revenues projected to reach hundreds of billions... Full story

Yahoo Finance • 10 months ago

Verastem director Gagnon sells $1604 in shares

Verastem, Inc. (NASDAQ:VSTM) Director Robert E. Gagnon sold 284 shares of common stock on June 16, 2025, at a price of $5.65, for a total transaction value of $1604. The transaction comes as VSTM shares have delivered an impressive 60% ret... Full story

Yahoo Finance • 10 months ago

Verastem's SWOT analysis: biotech stock poised for growth amid challenges

Verastem Oncology, Inc. (NASDAQ:VSTM) has recently transitioned into a commercial-stage biopharmaceutical company, marking a significant milestone in its corporate journey. With a market capitalization of $309 million, the company maintain... Full story

Yahoo Finance • 3 years ago

Verastem Oncology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, June 15, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it intends to offer and sell shares of its common st... Full story

Yahoo Finance • 3 years ago

Verastem Stock Is Outperforming 92% Of The Market — And It Just Surged

Verastem could be angling for an accelerated approval of its ovarian cancer treatment, an analyst said Thursday as she upgraded VSTM stock.... Full story

Yahoo Finance • 3 years ago

Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days

BOSTON, April 18, 2023--(BUSINESS WIRE)--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will present at the Stifel 2023 Virtual... Full story

Yahoo Finance • 3 years ago

Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Positive Interim Data Read-Out of RAMP 201 and Productive FDA Meeting Support Avutometinib + Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) Studies of Avutometinib Combinations in Other RAS Pathway-Driven Canc... Full story

Yahoo Finance • 4 years ago

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung Cancer Company Secured up to $150 M... Full story